Abstract
Necrotizing enterocolitis (NEC) is a microbiota- and feeding-related gut inflammatory disease in preterm infants. The standard of care (SOC) treatment for suspected NEC is antibiotic treatment and reduced enteral feeding, but how SOC treatment mitigates NEC remains unclear. We explored whether SOC treatment alone or combined with an anti-inflammatory protein (inter-alpha inhibitor protein, IAIP) supplementation improves outcomes in a preterm piglet model of formula-induced NEC. Seventy-one cesarean-delivered preterm piglets were initially fed formula, developing NEC symptoms by day 3, and then randomized into CON (continued feeding) or SOC groups (feeding cessation and antibiotics), each with or without human IAIP (2×2 factorial design). By day 5, IAIP treatment did not significantly influence outcomes, whereas SOC treatment effectively reduced NEC lesions, diarrhea, and bloody stools. Notably, SOC treatment improved gut morphology and function, dampened gut inflammatory responses, altered the colonic microbiota composition, and modulated systemic immune responses. Plasma proteomic analysis revealed the effects of SOC treatment on organ development and systemic inflammatory responses. Collectively, these findings suggest that SOC treatment significantly prevents NEC progression in preterm piglets via effects on gut structure, function, and microbiota, as well as systemic immune and inflammatory responses. Timely feeding cessation and antibiotics are critical factors in preventing NEC progression in preterm infants, while the benefits of additional human IAIP treatment remain to be established.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 117391 |
Tidsskrift | Biomedicine and Pharmacotherapy |
Vol/bind | 179 |
Antal sider | 13 |
ISSN | 0753-3322 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:The study was supported by internal funding at the University of Copenhagen and Takeda Pharmaceuticals. The study was designed, planned, interpreted, and financially supported in collaboration with Takeda Pharmaceuticals, a division of Plasma-Derived Therapies, Vienna, Austria. Takeda Pharmaceuticals assisted in interpreting results related to IAIP and did not hold final editorial rights. ZY was supported by a Ph.D. grant from the China Scholarship Council. RLS was funded by the BRIDGE - Translational Excellence Programme (bridge.ku.dk) of University of Copenhagen, funded by the Novo Nordisk Foundation [NNF18SA0034956].
Publisher Copyright:
© 2024 The Authors